Evommune Inc (EVMN) financials
Evommune revenue and earnings by year
Evommune's revenue was $13.0 million in the fiscal year to December 31, 2025, up 85.7% from the year before. Net income was -$68.9 million, -529.8% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 13 | 7 | 5 |
| Revenue growth | 85.7% | 40.0% | — |
| Operating income | -81 | -70 | -38 |
| Operating margin | -623.6% | -1000.2% | -757.0% |
| Net income | -69 | -67 | -34 |
| Net margin | -529.8% | -954.4% | -681.1% |
| Free cash flow | -77 | -58 | -30 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open EVMN in Markets.
See also: EVMN valuation and P/E history
No forecast, no recommendation. This page describes Evommune Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.